You just read:

Chimerix's CMX001 Shows Potential for Strong Antiviral Activity in Critically-Ill Immunocompromised Transplant Patients With Adenovirus Infection

News provided by

Chimerix, Inc.

Oct 22, 2010, 08:45 ET